SSPL WEALTH PVT LTD

Sunday 04 May, 2025 12:42 PM

Kotak Mahindra Bank Q4 PAT slides 14% YoY to Rs 3,552-cr Marico Q4 PAT rises 8% YoY to Rs 343 cr SBI Q4 PAT falls 10% YoY to Rs 18,643 crore; declares dividend of Rs 15.90/sh Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr Sunteck Realty registers PAT of Rs 50 crore in Q4; EBITDA margin at 33.5% Parag Milk Foods posts PAT of Rs 26 crore in Q4; EBITDA margin rises to 8.2% GOCL Corp inks deal to sell 100% stake in IDL Explosives for Rs 107 crore Aether Inds reports turnaround PAT of Rs 503 cr in Q4 FY25 NMDC iron ore production jumps 15% YoY in April'25 Eicher Motors CV sales climb 27% YoY in April'25 Godrej Agrovet Ltd leads losers in 'A' group Alembic Pharma receives USFDA approval for Ticagrelor tablets Ami Organics jumps after Q4 PAT soars to Rs 627 cr Malu Paper Mills Ltd leads losers in 'B' group Godrej Properties posts 19% YoY drop Q4 PAT; EBITDA at Rs 634 crore

Saravan Stocks

Hot Pursuit

Scrips, which has significant changes during the market hours.

Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr

03-May-25 15:12 Hrs IST

Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025.

On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024.

During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses.

Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year.

The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India ' a brand with over 25 years of legacy in the country.

The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants.

Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, 'We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.'

SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector.

Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofi's global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra', DePURA', Avil', and Combiflam'.

The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday.

Powered by Capital Market - Live News

Attention Investors :

Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.

Attention Investors :

Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.

Attention Investors :

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Attention Investors :

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

Email ID: info@ssplwealth.com Customers grievances : grievances@ssplwealth.com Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com, Mobile No: 7305522205

Hit Count : 40639116

Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified)